期刊文献+

HERG编码的钾离子通道与新药评价 被引量:4

HERG potassium channel and drug evaluation
原文传递
导出
摘要 由人类ether--àgo-go相关基因(HERG)编码的钾离子通道在人类生理、病理过程中扮演着十分重要的角色。在心肌细胞中,HERG钾通道影响心脏动作电位的复极过程,是绝大多数能引起心肌细胞QT间期延长药物的作用靶标,它已成为新药研发早期,评价候选化合物心脏毒性的分子靶标。 The K^+ channel encoded by the human ether-à-go-go related gene(HERG) plays a very important role in human physiological and pathological processes. HERG potassium channel determines the outward currents which facilitate the repolarization of the myocardial cells. Blockade of HERG channel usually results in a long QT interval and serious arrhythmia. Thus, HERG potassium channel has become a valuable target for screening leading compounds for QT interval prolongation in drug development program.
作者 赵杰 郑建全
出处 《军事医学科学院院刊》 CSCD 北大核心 2005年第4期386-389,共4页 Bulletin of the Academy of Military Medical Sciences
基金 国家自然科学基金资助项目(30371677)
关键词 HERG QT间期延长 药物评价 钾通道 HERG QT interval prolongation drug evaluation potassium channels
  • 相关文献

参考文献14

  • 1De Ponti F,Poluzzi E, Montanaro N. QT interval prolongation by non-cardiac drugs: lessons to be learned from recent experience[J]. Eur J Clin Pharmacol, 2000, 56(1): 1-18.
  • 2Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside[J]. Jpn J Pharmacol, 2000, 83(1): 1-19.
  • 3Petersen CI, McFarland TR, Stepanovic SZ, et al.In vivo identification of genes that modify ether-α-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia[J]. Proc Natl Acad Sci USA, 2004, 101(32):11773-11778.
  • 4Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals[J]. Proc Natl Acad Sci USA, 1994, 91(8): 3438-344.
  • 5Jiang C, Atkinson D, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity[J]. Nat Genet,1994, 8(2): 141.
  • 6Abbott GW, Sesti F, Splawski I, et al.MiRP1 forms Ikr potassium channels with HERG and is associated with cardiac arrhythmia[J]. Cell, 1999, 97(2): 175.
  • 7FU EY, Clemo HF, Ellen Bogen KA. Acquired QT prolongation: mechanism and implication[J]. Cardiol Rev,1998, 6(6): 319-324.
  • 8Roden DM, Spooner PM. Inherited long QT syndromes: A paradigm for understanding arrhythmogenesis[J]. J Cardiovasc Electrophysiol, 1999, 10(12): 1664-1683.
  • 9Netzer R, Ebneth A, Bischoff U, et al.Screening lead compounds for QT interval prolongation[J].Drug Discov Today, 2001, 6(2): 78-84.
  • 10Zhang MQ. Chemistry underlying the cardiotoxicity of antihistamines[J]. Curr Med Chem, 1997,4(3): 171-184.

同被引文献40

  • 1张海澄.继发性长QT综合征的常见原因[J].临床心电学杂志,2004,13(2):87-88. 被引量:8
  • 2李波.安全药理学的国内外发展概况[J].中国新药杂志,2004,13(11):964-968. 被引量:8
  • 3Harmar,A.J.,Hills.R.A.,Rosser,E.M..et al.IUPHAR-DB:the IUPHAR database of G protein-coupled receptors and ionchannels.Nucleic Acids Res.,2009;(37):D680-D685.
  • 4ANTZELEVITCH C. Heterogeneity and cardiac arrhythmias: an overview [ J ]. Heart Rhythm, 2007, 4 (7) :964.
  • 5WONG LC,BEHR ER. Acquired long QT syndrome: as risky as congenital long QT syndrome? [ J]. Europace, 2012, 14 ( 3 ) : 310 -311.
  • 6RODEN DM. Drug-induced prolongation of the QT interval[ J]. N Engl J Med,2004, 350 (10) : 1013 - 1022.
  • 7ICH Harmonized Tripartite Guideline El4. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs [ EB/OL]. [ 2005 - 05 - 12 ]. http :// www. fda. gov/eder/guidance/6922fn. 1 htm.
  • 8LEHTONEN A, FODSTAD H, LAITINEN-FORSBLOM P, et al. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes [ J ]. Heart Rhythm, 2007,4 ( 5 ) :603 - 607.
  • 9JEROEN A, AIMEE DC. Pharmaeogenomics and acquired long QT syndrome [ J ]. Pharmacogeomics, 2005,6 ( 3 ) :259 - 270.
  • 10AERSSENS J, PAULUSSEN AD. Pharmacogenomics and acquired long QT syndrome[ J]. Phama-ogenomics, 2005,6(3) : 259 -270.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部